University Hospital, Strasbourg, France

Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.

Phase 1/2, Not yet recruiting, 2026, 89 people, 1 Oct 2026, clinicaltrials.gov

Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction

Phase 3, Not yet recruiting, 2026, 568 people, 23 Mar 2026, clinicaltrials.gov

NCT05092984

Phase 3, Recruiting, 2022, 154 people, 26 Oct 2021, clinicaltrials.gov

NCT03216967

Phase 4, Completed, 2018, 130 people, 13 Jul 2017, clinicaltrials.gov

NCT02832713

Phase 2, Status unknown, 2017, 50 people, 14 Jul 2016, clinicaltrials.gov

NCT02714634

Phase 4, Recruiting, 2016, 286 people, 21 Mar 2016, clinicaltrials.gov

NCT02675647

Phase 4, Completed, 2015, 60 people, 5 Feb 2016, clinicaltrials.gov

NCT02176681

Phase 4, Completed, 2014, 70 people, 27 Jun 2014, clinicaltrials.gov

NCT01782235

Phase 2/3, Completed, 2013, 110 people, 1 Feb 2013, clinicaltrials.gov

NCT01756105

Phase 2, Terminated, 2012, 84 people, 24 Dec 2012, clinicaltrials.gov

NCT00811330

Phase 3, Status unknown, 2008, 60 people, 19 Dec 2008, clinicaltrials.gov

NCT00402376

Phase 4, Terminated, 2007, 20 people, 22 Nov 2006, clinicaltrials.gov

NCT00378729

Collaborator, Phase 4, Status unknown, 2006, 252 people, 21 Sept 2006, clinicaltrials.gov

NCT00369538

Phase 4, Suspended, 2006, 20 people, 29 Aug 2006, clinicaltrials.gov